SCHEMBL4013450

SCHEMBL4013450

NC(=O)c1nnc(-c2ccccc2)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
POLB P06746 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
PARP1 P09874 3/20 0.46
CHEK2 O96017 2/20 0.45
DHODH Q02127 2/20 0.44
PIN1 Q13526 3/20 0.43
CYP1A2 P05177 2/20 0.42
CASP1 P29466 2/20 0.42
CYP2C19 P33261 2/20 0.42
MAPK1 P28482 1/20 0.42
BRD4 O60885 1/20 0.40
BTK Q06187 1/20 0.40
BCAT2 O15382 1/20 0.40
MAP2 P11137 1/20 0.40
RNASEH1 O60930 1/20 0.39
ERCC1 P07992 1/20 0.39
FEN1 P39748 1/20 0.39
ERCC4 Q92889 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27894560 0.85 NPC1 (0.52) NPC1RAB9APOLBL3MBTL1DHODH
SCHEMBL28050441 0.83 NPC1 (0.50) NPC1RAB9APOLBL3MBTL1PARP1
SCHEMBL18662554 0.81 PRSS1 (0.45) NPC1RAB9APOLBL3MBTL1PARP1
SCHEMBL11238251 0.81 NPC1 (0.49) NPC1RAB9APOLBL3MBTL1PARP1
SCHEMBL3825935 0.80 PARP1 (0.54) NPC1RAB9APARP1PIN1
SCHEMBL15754676 0.80 NPC1 (0.47) NPC1RAB9APOLBL3MBTL1PARP1
SCHEMBL24380353 0.77 POLB (0.47) NPC1RAB9APOLBL3MBTL1PIN1
SCHEMBL24380269 0.77 L3MBTL1 (0.47) NPC1RAB9APOLBL3MBTL1PIN1
SCHEMBL384952 0.75 NPC1 (0.61) NPC1RAB9APOLBL3MBTL1PARP1
SCHEMBL2177064 0.74 MAPT (0.49) NPC1RAB9APOLBL3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074084-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-08-28 EP claimed
EP-2074084-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2009-07-01 EP claimed
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 US claimed
WO-2008039645-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 WO claimed
US-8829034-B2 Compounds which modulate the CB2 receptor Boehringer Ingerlheim International GmbH (DE) 2014-09-09 US disclosed
EP-2074084-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-08-28 EP disclosed
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain CNR2, CNR1, OPRL1 NPC1 2051/4885RAB9A 3649/4885POLB 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.